Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, United Kingdom.
Toronto Rehabilitation Institute, University Health Network, Toronto, Ontario, Canada.
JAMA. 2023 May 23;329(20):1745-1756. doi: 10.1001/jama.2023.6454.
Opioid use for chronic nonmalignant pain can be harmful.
To test whether a multicomponent, group-based, self-management intervention reduced opioid use and improved pain-related disability compared with usual care.
DESIGN, SETTING, AND PARTICIPANTS: Multicentered, randomized clinical trial of 608 adults taking strong opioids (buprenorphine, dipipanone, morphine, diamorphine, fentanyl, hydromorphone, methadone, oxycodone, papaveretum, pentazocine, pethidine, tapentadol, and tramadol) to treat chronic nonmalignant pain. The study was conducted in 191 primary care centers in England between May 17, 2017, and January 30, 2019. Final follow-up occurred March 18, 2020.
Participants were randomized 1:1 to either usual care or 3-day-long group sessions that emphasized skill-based learning and education, supplemented by 1-on-1 support delivered by a nurse and lay person for 12 months.
The 2 primary outcomes were Patient-Reported Outcomes Measurement Information System Pain Interference Short Form 8a (PROMIS-PI-SF-8a) score (T-score range, 40.7-77; 77 indicates worst pain interference; minimal clinically important difference, 3.5) and the proportion of participants who discontinued opioids at 12 months, measured by self-report.
Of 608 participants randomized (mean age, 61 years; 362 female [60%]; median daily morphine equivalent dose, 46 mg [IQR, 25 to 79]), 440 (72%) completed 12-month follow-up. There was no statistically significant difference in PROMIS-PI-SF-8a scores between the 2 groups at 12-month follow-up (-4.1 in the intervention and -3.17 in the usual care groups; between-group difference: mean difference, -0.52 [95% CI, -1.94 to 0.89]; P = .15). At 12 months, opioid discontinuation occurred in 65 of 225 participants (29%) in the intervention group and 15 of 208 participants (7%) in the usual care group (odds ratio, 5.55 [95% CI, 2.80 to 10.99]; absolute difference, 21.7% [95% CI, 14.8% to 28.6%]; P < .001). Serious adverse events occurred in 8% (25/305) of the participants in the intervention group and 5% (16/303) of the participants in the usual care group. The most common serious adverse events were gastrointestinal (2% in the intervention group and 0% in the usual care group) and locomotor/musculoskeletal (2% in the intervention group and 1% in the usual care group). Four people (1%) in the intervention group received additional medical care for possible or probable symptoms of opioid withdrawal (shortness of breath, hot flushes, fever and pain, small intestinal bleed, and an overdose suicide attempt).
In people with chronic pain due to nonmalignant causes, compared with usual care, a group-based educational intervention that included group and individual support and skill-based learning significantly reduced patient-reported use of opioids, but had no effect on perceived pain interference with daily life activities.
isrctn.org Identifier: ISRCTN49470934.
慢性非恶性疼痛患者使用阿片类药物可能会产生危害。
检验一种多组分、基于群组的自我管理干预是否能够减少阿片类药物的使用,并改善与疼痛相关的残疾,与常规护理相比。
设计、地点和参与者:在英格兰的 191 个基层医疗中心开展的多中心、随机临床试验,共纳入 608 名服用强阿片类药物(丁丙诺啡、双氢可待因酮、吗啡、海洛因、芬太尼、氢吗啡酮、美沙酮、羟考酮、罂粟碱、喷他佐辛、哌替啶、曲马多)治疗慢性非恶性疼痛的成年人。该研究于 2017 年 5 月 17 日至 2019 年 1 月 30 日进行,最后一次随访时间为 2020 年 3 月 18 日。
参与者以 1:1 的比例随机分为常规护理组或为期 3 天的群组治疗组,该组侧重于技能学习和教育,辅以由护士和非专业人员提供的为期 12 个月的一对一支持。
主要结局为患者报告的结局测量信息系统疼痛干扰简表 8a(PROMIS-PI-SF-8a)评分(T 评分范围,40.7-77;77 表示疼痛干扰最严重;最小临床重要差异,3.5)和 12 个月时停止使用阿片类药物的参与者比例,通过自我报告进行测量。
608 名随机参与者(平均年龄 61 岁;362 名女性[60%];中位数每日吗啡等效剂量 46 mg [IQR,25-79])中,440 名(72%)完成了 12 个月的随访。两组在 12 个月的随访中,PROMIS-PI-SF-8a 评分没有统计学差异(干预组-4.1,常规护理组-3.17;组间差异:平均差异-0.52 [95%CI,-1.94 至 0.89];P = .15)。在 12 个月时,干预组 225 名参与者中有 65 名(29%)停止使用阿片类药物,常规护理组 208 名参与者中有 15 名(7%)停止使用阿片类药物(比值比,5.55 [95%CI,2.80 至 10.99];绝对差异,21.7% [95%CI,14.8%至 28.6%];P < .001)。干预组 305 名参与者中有 8%(25 名)发生严重不良事件,常规护理组 303 名参与者中有 5%(16 名)发生严重不良事件(P = .004)。最常见的严重不良事件是胃肠道(干预组 2%,常规护理组 0%)和运动/肌肉骨骼(干预组 2%,常规护理组 1%)。干预组有 4 人(1%)因疑似或可能的阿片类药物戒断症状(呼吸急促、热潮红、发热和疼痛、小肠出血和过量自杀企图)而接受了额外的医疗护理。
与常规护理相比,对于非恶性原因引起的慢性疼痛患者,基于群组的教育干预包括群组和个体支持以及技能学习,可显著减少患者报告的阿片类药物使用,但对日常生活活动中疼痛干扰的感知没有影响。
国际标准随机对照试验注册平台(ISRCTN)标识符:ISRCTN49470934。